Trials / Active Not Recruiting
Active Not RecruitingNCT04618913
Anticoagulation in Patients With Venous Thromboembolism and Cancer
VICTORIE (VTE In Cancer - Treatment, Outcomes and Resource Use In Europe)
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns,healthcare resource utilisation (HCRU), direct and indirect costs (where feasible), and safety and effectiveness outcomes in patients with VTE and active cancer or patients with VTE and history of cancer who initiate anticoagulant treatment with a VKA, LMWH or NOACs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apixaban | Anticoagulant |
| DRUG | Rivaroxaban | Anticoagulant |
| DRUG | Edoxaban | Edoxaban |
| DRUG | Dabigatran | Dabigatran |
| DRUG | VKA | Vitamin K antagonist |
| DRUG | LMWH | Low Molecular Weight Heparin |
Timeline
- Start date
- 2020-12-14
- Primary completion
- 2026-04-06
- Completion
- 2026-04-06
- First posted
- 2020-11-06
- Last updated
- 2026-03-12
Locations
1 site across 1 country: United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04618913. Inclusion in this directory is not an endorsement.